MYRIAD GENETICS INC (MYGN) research
MYRIAD GENETICS INC- Sector
- Biotechnology
- Last price
- $4.54
- As of
MYRIAD GENETICS INC (MYGN): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-16.
As of . Source: SEC EDGAR filings for MYGN. Method and limitations.
Share the MYGN intelligence card
See the full MYGN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MYGN on one page. Preview it with sample data, then open it live with a free account.
Preview the MYGN dossierActive signals for MYGN
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 75% of MYGN (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 87% of MYGN (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 80% of MYGN (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +860% to MYGN (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 323.7%, EPS $-0.25 vs $-0.059 estimate
FREE, NO ACCOUNT
Every signal on MYGN, as it fires
You are seeing 5 of 10 signals recorded on MYGN since 2026-06-02.
The five above landed across 2 days. The other 5 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MYGN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 62855J104 · 2026Q2 | $37.8M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 62855J104 · 2026Q2 | $26.2M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 62855J104 · 2026Q2 | $8.9M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 62855J104 · 2026Q2 | $8.8M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 62855J104 · 2026Q2 | $1.4M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MYGN
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
MYGN against its peers
MYGN's operating margin of -47.0% ranks in the 73rd percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | MYGN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 825M USD | 42.6M USD | 96 | 12 |
| Gross margin | 69.9% | n/a | n/a | 1 |
| Operating margin | -47.0% | -242.4% | 73 | 12 |
| Net margin | -44.4% | -221.7% | 73 | 12 |
| Return on equity | -99.4% | -68.2% | 28 | 19 |
Peers (21): KYTX, SPRY, EDIT, RLMD, ZURA, TTRX, GALT, INDP, PRTA, RZLT, TECX, CCCC, DMAC, AGEN, IRD, ENTA, ARCT, ENTX, ASMB, OVID, FENC. Left out: SCTX (no annual filing), EIKN (no annual filing), PRTC (period gap), AGMB (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (MYGN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more MYGN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to MYGNand get the insider, 13F, options, and confluence read in one view.